Pulmonx Corp (LUNG)
| Market Cap | 79.02M+3.4% |
| Revenue (ttm) | 87.44M-3.4% |
| Net Income | -48.12M+15.5% |
| EPS | -1.19+19.6% |
| Shares Out | 42.95M |
| PE Ratio | n/a |
| Forward PE | -1.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 358 |
| Open | 1.84 |
| Previous Close | 1.84 |
| Day's Range | 1.84 - 1.84 |
| 52-Week Range | 1.13 - 2.89 |
| Beta | 0.34 |
| Analysts | none |
| Price Target | 3.40(+84.78%) |
| Earnings Date | Nov 11, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About LUNG
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$LUNG stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LUNG holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LUNG's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LUNG Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LUNG Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LUNG patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LUNG from public contracts
Source: USAspending.gov
LUNG Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LUNG’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score